Doximity's Chief Accounting Officer Siddharth Sitaram sold 5,652 shares worth $140,400 in mid-August. The transaction was driven by routine tax obligations from option exercises and restricted stock unit vesting rather than a loss of confidence in the company. Sitaram retains significant equity holdings of 93,122 shares. The sale reflects standard tax-driven liquidity management common among executives.

Doximity's president Steven Zatz sold 4,482 shares worth $111,154 on August 15 through a routine tax withholding transaction upon restricted stock unit vesting. Zatz retains 51,864 directly held shares valued at $1.29 million, but his significant upside exposure comes from 150,000 options granted in July with a $20.49 strike price that don't vest until July 2027. The timing is notable given Doximity's recent earnings showed 7% revenue growth but margin compression due to higher-than-expected AI compute costs, with the CFO characterizing this as a 'good problem' as AI search revenue recognition is expected in Q3.

Doximity's new CFO Matthew Sonefeldt sold 15,311 shares worth $380,000 in a non-discretionary transaction tied to restricted stock unit vesting and tax obligations. The sale reduced his holdings by only 3%, leaving him with a $12.1 million equity stake. The filing comes as the company faces slowing growth with Q3 guidance at only 1% growth midpoint, tight pharma spending, and margin pressure from AI compute costs, though management expects improvement in Q3 when AI search revenue lands.

Doximity CEO Jeffrey Tangney sold 8,505 shares (~$211,000) on August 15 to cover tax withholding on vesting equity awards—a non-discretionary transaction that reduced his holdings by only 0.3%. While the insider transaction itself is unremarkable, the underlying business faces headwinds: Q1 revenue grew just 7%, gross margins compressed due to AI compute costs, adjusted EBITDA fell 6%, and net income dropped significantly. The stock has cratered over 60% in the past year as the company invests heavily in AI with revenue recognition delayed until Q3.

Atlassian and Doximity surged over 30% after earnings by exceeding low expectations with strong AI adoption. Three similar SaaS stocks—GitLab, UiPath, and Asana—have comparable setups with low expectations, high short interest, and emerging AI solutions that could drive significant post-earnings gains.

Doximity shares surged 32.62% after management revealed strong returns on AI investments. The company's AI assistant, Doximity Ask, topped independent clinical AI model rankings with the lowest error rates. Management highlighted that AI Search generates over 10x revenue compared to operational costs, with AI prompt volume up 25% quarter-over-quarter and AI Scribe users growing 10x year-over-year.

Doximity stock has plummeted 56% in 2026 amid concerns that AI could disrupt its medical platform services. However, the author argues these fears are overblown, citing the company's dominant 85%+ physician network, strong customer base (top 20 pharma companies and hospital systems), and regulatory barriers that protect it from easy disruption. Trading at 15x free cash flow, the author views it as a buying opportunity as pharma advertising spending should eventually rebound.

The Dow Jones climbed back above 50,000 driven by Cisco's strong earnings beat and guidance raise, while Nvidia gained on news of Chinese H200 chip approvals. However, the rally appears fragile as inflation data runs hot with import prices spiking 1.9% and energy costs surging, offsetting positive consumer resilience metrics. The Trump-Xi summit in Beijing provided mild sentiment support but delivered limited concrete deliverables.

Doximity stock fell 24% after reporting mixed Q4 2026 earnings with only 5% sales growth and disappointing 2027 guidance of 3-5% revenue growth. The company is increasing AI spending amid a soft healthcare advertising market, pressuring profitability. Despite industry headwinds, Doximity maintains its market leadership with 85% of U.S. physicians on its platform and trades at a cheap 12x forward earnings valuation.

U.S. stock futures rose on Thursday as President Trump addresses trade issues with China. Cisco Systems surged 18.8% on better-than-expected Q3 results and raised FY26 guidance. Doximity plunged 21.46% on mixed Q4 results and weak guidance. Grocery Outlet gained 16.41% after beating EPS estimates by 150%. The Fed is expected to hold rates steady in June with 98.6% probability. Nvidia's H200 chip sales to Chinese firms were cleared by the U.S., though Beijing halted deliveries.

Tech stocks surged on Wednesday despite a hotter-than-expected April PPI reading (6% YoY vs 4.8% expected), which rekindled inflation concerns. The Nasdaq 100 gained 0.7% led by semiconductor strength, while rate-sensitive sectors like utilities and financials declined. Nvidia hit record highs above $226 ahead of earnings, Ford surged 11.9% on strong Q1 results, and software stocks like Dynatrace and Doximity fell sharply on disappointing earnings.

Hot inflation data (April PPI up 1.4% vs 0.5% consensus) has forced markets to reprice lower rate-cut expectations, pressuring equities and extending Treasury yields to 4.475%. While semiconductor stocks rallied on Trump's Beijing summit and memory pricing strength, the broader market faces stretched valuations with asymmetric earnings reaction patterns favoring misses over beats. Kevin Warsh is set to become Fed chair amid the worst macro moment for establishing credibility.